Novira Therapeutics, Inc.

Developing first-in-class antiviral therapeutics based on a novel mechanism of action that targets viral capsid assembly. Acquired by Johnson & Johnson in December 2015.

Exited Portfolio Company

www.noviratherapeutics.com

Other Companies